Drugs / Moderna COVID-19 Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04761822 | Apr 2021 → Apr 2022 | COVID-19, hypersensitivity reaction disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT05028257 | Sep 2021 → May 2023 | anaphylaxis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04811664 | Mar → Dec 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 3 | NCT04806113 | Mar → Jun 2021 | COVID-19, rheumatoid arthritis, systemic lupus erythematosus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06441955 Comparator | Mar 2024 → Sep 2030 expected | long COVID-19 | Well- Konnect Healthcare Services and Research Firm | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moderna COVID-19 Vaccine | “Moderna COVID19 vaccine” NCT05028257 ↗ |
| Modality | Vaccine | “The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.” NCT04761822 ↗ |
| Route | Intramuscular | “The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.” NCT04761822 ↗ |